𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Plasma levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin in patients with neuroblastoma

✍ Scribed by Donatella Granchi; Alberto Garaventa; Ilaria Amato; Paolo Paolucci; Nicola Baldini

Publisher
John Wiley and Sons
Year
2006
Tongue
French
Weight
141 KB
Volume
119
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Earlier reports showed that the balance between receptor activator of nuclear factor‐κB ligand (RANKL) and its decoy‐receptor osteoprotegerin (OPG) plays an important role in the pathogenesis of metastatic osteolysis induced by neuroblastoma cells. In this study, we investigated whether circulating levels of OPG, RANKL and their ratio were associated to the presence of osteolytic lesions in advanced neuroblastoma, as well as whether they provided additional information on the severity and prognosis of the disease. Plasma levels of RANKL and OPG were measured in 54 newly diagnosed neuroblastomas; 27 of them showed metastatic disease (stage IV), including 19 bone dissemination. Thirty‐five children who were admitted to the pediatric department for minor surgical problems served as control group. OPG was significantly lower in all patients compared with controls, while RANKL levels were significantly increased in advanced neuroblastoma. OPG‐to‐RANKL ratio decreased in stage‐IV patients, and particularly in those who had bone metastases. The diagnostic accuracy of the OPG‐to‐RANKL ratio in discriminating the presence of osteolytic lesions was not confirmed statistically. OPG correlated significantly with other prognostic factors, namely, ferritin and neurone‐specific enolase. In addition, an inverse relationship was found between OPG and event‐free survival, and it was more significant in patients who had bone metastasis. This pilot study confirms that the production of OPG and RANKL is disregulated in neuroblastoma. Although the OPG‐to‐RANKL ratio does not have a predictive value in detecting bone metastasis, the measurement of the previously mentioned markers could be useful in decisions regarding the use of adjuvant therapies. © 2006 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Effects of disease-modifying antirheumat
Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor κB, osteoprotegerin, and receptor activator of nuclear factor κB ligand
✍ Chang-Keun Lee; Eun Young Lee; Son Mi Chung; Se Hwan Mun; Bin Yoo; Hee-Bom Moon 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 649 KB

## Abstract ## Objective To demonstrate the effects of disease‐modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through their effects on receptor activator of nuclear factor κB (RANK), osteoprotegerin (OPG), and RANK ligand (RANKL). ## Methods Peripheral b

In vitro blockade of receptor activator
In vitro blockade of receptor activator of nuclear factor-κB ligand prevents osteoclastogenesis induced by neuroblastoma cells
✍ Donatella Granchi; Ilaria Amato; Luca Battistelli; Sofia Avnet; Sergio Capacciol 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 550 KB

## Abstract Proliferation and differentiation of osteoclasts are regulated by a cytokine system that includes RANKL, which binds 2 receptors: RANK, which activates osteoclast differentiation, and osteoprotegerin (OPG), a decoy receptor that limits RANKL action. We investigated the role of the OPG/R

High levels of osteoprotegerin and solub
High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti–tumor necrosis factor α treatment
✍ Maria Ziolkowska; Mariola Kurowska; Anna Radzikowska; Grazyna Luszczykiewicz; Pi 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 2 views

## Abstract ## Objective To test the hypotheses that 1) proinflammatory cytokines affect osteoprotegerin (OPG) and soluble receptor activator of nuclear factor κB ligand (sRANKL) production and therefore the OPG and sRANKL levels differ in rheumatoid arthritis (RA) patients in comparison with heal

Receptor activator of nuclear factor-κB
Receptor activator of nuclear factor-κB ligand and osteoprotegerin : Potential implications for the pathogenesis and treatment of malignant bone diseases
✍ Lorenz C. Hofbauer; Andreas Neubauer; Armin E. Heufelder 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 1 views

## Background: The current review summarizes the roles of the ligand, receptor activator of nuclear factor-kappab ligand (rankl), its receptor, receptor activator of nuclear factor-kappab (rank), and its decoy receptor, osteoprotegerin (opg), on osteoclast biology and bone resorption. furthermore,

Low levels of arsenite activates nuclear
Low levels of arsenite activates nuclear factor-κB and activator protein-1 in immortalized mesencephalic cells
✍ Kumar Felix; Sunil K. Manna; Kimberly Wise; Johnny Barr; Govindarajan T. Ramesh 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 267 KB

## Abstract Degeneration of dopaminergic neurons is one of the major features of Parkinson's disease. Many redox‐active metals such as iron and manganese have been implicated in neuronal degeneration characterized by symptoms resembling Parkinson's disease. Even though, arsenic, which is another re